RECREATE - A retrospective chart review to assess the treatment reality for mRCC patients following 1st line Pazopanib: reflecting a changing mRCC treatment landscape (2017) Hegele A, Van Der Heyde E, Goebell P, Zengerling F, Hbner A, Klier J, Belz H, et al. Conference contribution Biological and clinical effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+/HER2-breast cancer (2017) Fasching P, Fernandez Abad M, Garcia-Saenz JA, Schneeweiss A, Guarneri V, Colleoni M, Petru E, et al. Conference contribution Treatment reality and outcome data of patients with advanced papillary renal cell carcinoma - data from the German prospective RCC-Registry (2017) Staehler M, Goebell P, Mueller L, Overkamp F, Frank M, Kruggel L, Jaenicke M, Marschner N Conference contribution Evaluation of meaningful change in bowel move frequency for patients with carcinoid syndrome (2017) Pavel ME, Gable J, Kulke MH, Bergsland E, Anthony LB, Caplin ME, Oberg KE, et al. Conference contribution Bevacizumab (Bev)-based combinations across treatment lines in patients (pts) with metastatic colorectal cancer (mCRC) - interim results from a German non-interventional study (KORALLE) (2017) Eggers E, Uhlig J, Reichert D, Wein A, Schulz H, Beringer A, Arnold D Conference contribution Extension study to the open-label, multi-center, expanded access study of everolimus in patients with advanced neuroendocrine tumors (2017) Doerffel Y, Kullmann F, Lammert F, Quietzsch D, Schöfl C, Schuppert F, Weber M, et al. Conference contribution Combined lanreotide autogel and temozolomide in progressive neuroendocrine tumours: an interim safety analysis of the SONNET study (2017) Hoersch D, Raderer M, Lahner H, Rinke A, Denecke T, Koch A, Raspel A, et al. Conference contribution Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach (2016) Schöffski P, Wozniak A, Schöffski O, van Eycken L, Debiec-Rychter M Journal article, Original article DasPAQT: Treating Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib - PCR-Monitoring, Adherence, Quality of Life, Therapy Satisfaction (OMC 2014-I; BMS CA180-565) (2016) Tesch H, Pelz H, Janssen J, Hansen R, Fietz T, Anhuf J, Häberle L, et al. Conference contribution DasPAQT: Treating patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) with Dasatinib: PCR-Monitoring, adherence, quality of life, therapy satisfaction (OMC 2014-I; BMS CA180-565) - an analysis of the first 150 patients (2016) Tesch H, Pelz H, Janssen J, Hansen R, Fietz T, Anhuf J, Häberle L, et al. Conference contribution